Alpha Tau Medical Ltd (NASDAQ: DRTS) is a Healthcare company in the Medical - Equipment & Services industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
13.49
+0.35+2.66%
Earnings
Up 2.7% — Reported earnings — EPS missed by 110%.
High confidence
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 0.18% | Shs Outstand | 90.33M | Perf Week | 11.45% |
| Market Cap | 1.19B | Forward P/E | - | EPS next Y | -0.51 | Insider Trans | -69.01% | Shs Float | 61.99M | Perf Month | 1.23% |
| Enterprise Value | 1.19B | PEG | 0.56 | EPS next Q | - | Inst Own | 5.04% | Short Float | 4.81% | Perf Quarter | 67.39% |
| Income | -57.33M | P/S | 0.00 | EPS this Y | - | Inst Trans | - | Short Ratio | 3.41 | Perf Half Y | 91.55% |
| Sales | 0.00 | P/B | 17.00 | EPS next Y | 21.84% | ROA | -52.29% | Short Interest | 2.98M | Perf YTD | 165.45% |
| Book/sh | - | P/C | - | EPS next 5Y | - | ROE | -73.23% | 52W High | 14.49 -6.87% | Perf Year | 319.81% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | -46.51% | 52W Low | 3.08 338.00% | Perf 3Y | 246.70% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | 0.00% | Volatility | 5.31% 6.78% | Perf 5Y | 33.67% |
| Dividend TTM | - | EV/Sales | 0.00 | EPS Y/Y TTM | -48.89% | Oper. Margin | 0.00% | ATR (14) | 0.83 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 7.79 | Sales Y/Y TTM | - | Profit Margin | 0.00% | RSI (14) | 58.19 | Recom | 2.17 |
| Dividend Gr. 3/5Y | - | Current Ratio | 7.79 | EPS Q/Q | -116.67% | SMA20 | 4.72% | Beta | 1.17 | Target Price | 13.33 |
| Payout | 0.00% | Debt/Eq | 0.21 | Sales Q/Q | - | SMA50 | 14.70% | Rel Volume | 0.33 | Prev Close | 13.14 |
| Employees | 121 | LT Debt/Eq | 0.16 | Earnings | Aug 10 | SMA200 | 69.75% | Avg Volume | 896.38K | Price | 13.49 |
| IPO Date | Mar 08, 2021 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -110.42% - | Net Debt/EBITDA | -0.13 | Volume | 292,198 | Change | 2.66% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jun-04-26 | Reiterated | Barclays | Overweight | $15 → $17 |
| May-28-26 | Reiterated | Barclays | $15 | |
| May-19-26 | Reiterated | Piper Sandler | Neutral | $7.00 → $8.00 |
| May-12-26 | Reiterated | HC Wainwright & Co. | Buy | $12 → $15 |
| Mar-04-26 | Downgrade | Piper Sandler | Overweight → Neutral | |
| Feb-24-26 | Reiterated | HC Wainwright & Co. | Buy | $9.00 → $12 |
| Sep-03-25 | Reiterated | HC Wainwright & Co. | Buy | $9.00 |
| May-21-24 | Reiterated | Piper Sandler | Overweight | $12 → $7.00 |
| Nov-23-22 | Reiterated | Piper Sandler | Overweight | $12 |
Latest News
Jul-22-26
Jul-22-2612:09PM
Jul-21-26
Jul-21-2608:30AM
Jul-19-26
Jul-17-26
Jul-15-26
Jul-15-2608:30AM
Jul-07-26
Jul-02-26
Jun-23-26
Jun-23-2608:33AM
Jun-12-26
Company
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company is headquartered in Jerusalem, Israel.
Ownership
Total institutional ownership5.04%
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 1 | 1 | 1 | — | — | — | — | |
| Gross Profit | -1 | -1 | -1 | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 10 | 8 | 9 | — | — | — | — | |
| Research and Development | 31 | 27 | 26 | — | — | — | — | |
| Other Operating Expense | 0 | 0 | 0 | — | — | — | — | |
| Operating Income | -42 | -36 | 36 | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 0 | 5 | -65 | — | — | — | — | |
| Net Income Before Taxes | -43 | -32 | -29 | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | — | — | — | — | |
| Consolidated Net Income | -43 | -32 | -29 | — | — | — | — | |
| Net Income From Continuing Operations | -43 | -32 | -29 | — | — | — | — | |
| Net Income | -43 | -32 | -29 | — | — | — | — | |
| EPS (Recurring) | -0.53 | -0.45 | -0.42 | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.53 | -0.45 | -0.42 | — | — | — | — | |
| EPS (Diluted) | -0.53 | -0.45 | -0.42 | — | — | — | — | |
| EBITDA | -41 | -30 | -28 | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | — | — | |
| Gross Margin | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | |
| Shares Outstanding | 81 | 70 | 69 | — | — | — | — | |
| Market Capitalization | 401 | 217 | 208 | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Levy Raphi | Chief Financial Officer | Jul 06 '26 | Option Exercise | 2.98 | 2,270 | 6,765 | 92,450 | Jul 07 |
| Levy Raphi | Chief Financial Officer | Jul 06 '26 | Sale | 14.00 | 2,270 | 31,782 | 90,180 | Jul 07 |
| Levy Raphi | Chief Financial Officer | Jul 02 '26 | Option Exercise | 2.98 | 17,873 | 53,262 | 108,053 | Jul 06 |
| Levy Raphi | Chief Financial Officer | Jul 02 '26 | Sale | 13.00 | 17,873 | 232,397 | 90,180 | Jul 06 |
| Levy Raphi | Chief Financial Officer | Jul 01 '26 | Option Exercise | 2.98 | 2,127 | 6,338 | 92,307 | Jul 02 |
| Levy Raphi | Chief Financial Officer | Jul 01 '26 | Sale | 13.02 | 2,127 | 27,691 | 90,180 | Jul 02 |
| Levy Raphi | Chief Financial Officer | Jun 30 '26 | Sale | 12.00 | 20,000 | 240,044 | 90,180 | Jul 01 |
| Levy Raphi | Chief Financial Officer | Jun 25 '26 | Sale | 11.00 | 20,000 | 220,004 | 110,180 | Jun 26 |
| Levy Raphi | Chief Financial Officer | Jun 23 '26 | Sale | 9.55 | 17,500 | 167,051 | 130,180 | Jun 25 |
| Levy Raphi | Chief Financial Officer | Jun 03 '26 | Sale | 10.83 | 32,500 | 352,116 | 147,680 | Jun 04 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.